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Abstract 
 
Based on recent results, the determination of the easily accessible red blood cell (RBC) 
membrane proteins may provide new diagnostic possibilities for assessing mutations, 
polymorphisms, or regulatory alterations in diseases. However, the analysis of the current mass 
spectrometry based proteomics data sets and other major databases indicates inconsistencies – 
the results show large scattering and only a limited overlap for the identified RBC membrane 
proteins. Here we applied membrane specific proteomics studies in human RBC, compared these 
results to the data in the literature, and generated a comprehensive and expandable database 
using all available data sources. The integrated web database now refers to proteomic, genetic 
and medical databases as well, and contains an unexpected large number of validated membrane 
proteins previously thought to be specific for other tissues and/or related to major human 
diseases. Since the determination of protein expression in RBC provides a method to indicate 
pathological alterations, our database should facilitate the development of RBC membrane 
biomarker platforms and provide a unique resource to aid related further research and 
diagnostics. 
Database URL: http://rbcc.hegelab.org 
4 
 
Introduction 
A significant portion (about 30%) of the human proteome consists of membrane proteins and 
their mutants and polymorphic variants are involved in numerous diseases providing the 
molecular targets of most of the marketed drugs (1,2). Due to a multi-step processing and 
complex regulation of membrane protein expression, in most cases the DNA or mRNA-based 
information cannot provide appropriate diagnostic information, and only direct protein 
determinations can serve as proper medical biomarkers. However, tissue sample collection, and 
the lack of accuracy and sensitivity for quantitative membrane protein detection are the limiting 
factors in this regard. 
A major set of membrane biomarkers is provided by the Cluster of Differentiation (CD) 
system (see http://www.hcdm.org), mostly applied in hematology and immunology. This set 
(continuously updated and supervised by the Human Cell Differentiation Markers Workshop 
(3,4)) contains now over 500 cell surface markers, including glycoproteins, glycosylated lipids, 
and carbohydrates, all playing important roles in cell function, differentiation and activation. The 
main advantage of the CD system is that its markers can be detected by validated antibodies and 
some of them (although still a minority) are routinely used in diagnostic laboratories. Thus, the 
results provide valuable information of disease states even without knowing the exact identity 
and function of a given marker. However, a major limitation of this system for membrane 
proteins is that it includes only those recognized by well described antibodies, and the 
quantitation of the CD marker in most cases is inappropriate. 
Mass spectrometry based proteomics may provide both qualitative and quantitative data for 
membrane protein expression. However, integral membrane proteins are variably recognized by 
these methods and further difficulties are related to the sampling and quantification of large and 
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hydrophobic membrane proteins (5-8). Since most of the MS approaches do not focus on 
membrane proteins, they have an inevitable bias towards cytoplasmic proteins. In addition, the 
need of expensive major equipment hinders their wide-spread diagnostic applications in routine 
clinical laboratories.  
In the case of the human red blood cells (RBC), the limitations of tissue sample collection 
and continuous intracellular membrane protein trafficking are not affecting membrane protein 
determinations. Small blood samples are easy to collect and contain a relatively large number of 
RBC (about 5 x l0
6 
cells in one microliter), which have only a single plasma membrane. Several 
recent studies suggest that uncovering the red cell membrane proteome may provide the basis of 
valuable diagnostic tools (9-11). However, even highly purified RBC samples may contain 
immature or contaminating cells, and minor contaminants may have a major impact on the 
results of proteomics. Thus a vigorous control is necessary in this regard.  
There have been numerous studies using different approaches (e.g. mass spectrometry, 2-D 
electrophoresis, and antibody detection) attempting to describe the RBC membrane proteome 
(8,11). CD markers for the RBC are available, and the blood group systems are also provided in 
major databases. Surprisingly, we found major inconsistencies in these data, thus their medical 
diagnostic use is hampered by the contrasting findings, the ambiguous protein names, outdated 
database identifiers, and the variable format of data. Mining information on RBC proteins from 
laborious reviews merging data from different studies (6,10) is still extremely difficult, and 
currently there is no available central and searchable database for the membrane proteins 
expressed in RBCs.  
In the present study we aimed to generate a tool for the personalized medical diagnosis of 
diseases associated with membrane proteins, by establishing an integrated platform of the RBC 
membrane proteome. First, we performed MS studies on human red blood cell membrane 
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preparations which were further washed in alkaline milieu to remove cytoplasmic and 
extracellular adhering proteins. Later, we compared our dataset with other MS-based, CD 
cluster-defined, and blood group specific databases. Based on these results, we have generated 
an integrated database based on various RBC-relevant sources, for a research and diagnostic 
biomarker application of the RBC membrane proteome. 
 
Methods 
Mass spectrometry analysis of red cell membrane proteins 
RBC ghost preparation: Membrane was prepared from 50 mL of blood provided by healthy 
donors with a written consent in a project with approved ethical committee permission. This 
study was approved by the regional ethical committees (Department of Health, Office of 
Hungarian Government, Budapest, Hungary), and all procedures were performed in accordance 
with the Declaration of Helsinki. RBC was isolated and red blood cell membranes (ghosts) were 
prepared according to the original methods described by Schatzmann and Rossi (12) and Wolf 
(13). These processes involved the removal of contaminating cells, including platelets and white-
blood cells (confirmed by flow cytometry examinations), during several washes of the red cells. 
In the flow cytometry measurements RBCs were labelled with WGA-Alexa488, while Draq5 
nuclear stain was used to visualize all white blood cells. For selectively labeling the platelets, an 
FITC-conjugated anti-CD61 antibody was applied. We found that after three washes of the blood 
samples, the RBC / total WBC ratio decreased from an original mean value of 0.27% to 0.0002%, 
while the RBC / platelet ratio decreased from a mean of 2.47% to 0.011%. This means the 
presence of about 2 WBC / 10
6
 RBC, and about 1 platelet / 10
4
 RBC in the final RBC 
preparation. Potential reticulocyte contamination was also examined by Giemsa staining of the 
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RBC preparation, and reticulocyte count after three washes (removing the upper layer of RBCs) 
decreased from 2% to less than 0.02%. In order to remove any membrane-associated cytoplasmic 
or plasma proteins from ghosts, the white RBC membranes (5 mg protein/ml) were diluted with 
20-fold volume of 0.5 mM Tris/HCl, 0.05 mM DTT (pH 8.5), incubated for 30 min at 4°C and 
for 15 min at 37°C, then homogenized with a 27 gauge needle. The membranes were further 
washed first with 10 mM Tris/HCl,  0.5 mM EDTA, pH 8.0, and then twice with large volumes 
of 10 mM Tris/HCl, pH 7.4. The membranes were resuspended at 2 mg protein/ml in 140 mM 
KC1and 20 mM Tris/HCl, pH 7.4 and kept frozen until further use.  
Membrane protein extraction:  Erythrocyte membrane (ghost) extraction with carbonate to 
remove adhering proteins was performed according to Fujiki et al. (14) in the presence of Mini 
complete protease inhibitor (Roche Applied Biosystems, Switzerland) for 1 h at 4°C. Extracted 
membranes were collected after ultracentrifugation for 1 h at 100,000gav. The supernatant was 
discarded and the pellet was resuspended in 200 µl sucrose (250 mM) using a syringe with a 
25G needle. The protein estimation was carried out using BCA protein assay kit (Interchim, 
France). 
In-solution Digestion: 200 µg of protein was first deglycosylated with PNGase F (NEB) at 
37°C (overnight at 500 rpm, at RT (15)). The sample was diluted with 20 mM ammonium 
bicarbonate (pH 8) and 0.1% Rapigest SF surfactant (Waters,USA). The proteins were reduced 
using 5 mM DTT (30 minutes at 60°C, 700 rpm) followed by alkylation with 45 mM 
iodoacetamide (10 minutes at RT in the dark). The reaction was quenched by adding 30 mM 
DTT (10 minutes at RT). The resulting sample was first digested using trypsin (sequencing 
grade; Promega, Switzerland) at a ratio of 1:20 (3.5 h at 37°C at 700 rpm) followed by 
centrifugation for 10 minutes,13000g) and supernatant (S1) was collected. The pellet was further 
8 
 
digested with chymotrypsin and trypsin at a ratio of 1:1 (overnight at 37°C at 700 rpm). The 
reaction was stopped by adding 50% acetonitrile and 0.1% trifluroacetic acid (TFA) (37°C, 30 
minutes at 700 rpm) and the supernatant was collected (S2).  S1 and S2 were pooled for further 
analysis.  
Pre-fraction by Strong Cation Exchange (SCX): Peptides obtained above were vacuum dried, 
resuspended in buffer A (10 mM KH2PO4, pH 2.7, in 25% acetonitrile), and loaded onto a 
2.1 × 200 mm polysulfoethyl aspartamide A column (PolyLC, USA) on an Agilent HP1100 
binary HPLC system (Agilent Technologies, USA ). Peptides were eluted with an increasing 
KCl gradient (10–40 min, 0–30% buffer B; 40–60 min 30–100% buffer B;  10 mM KH2PO4, pH 
2.7, and 500 mM KCl in 25% acetonitrile) and fractions of ~0.6 ml collected. Eluted peptides 
were pooled into seventeen fractions based on the chromatogram, and desalted using Ziptips 
(Millipore, Switzerland) following the vendors protocol.  
MS analysis: Desalted samples were vacuum concentrated and resuspended in 3% 
acetonitrile and 0.1% formic acid, before injecting on LTQ Orbitrap XL mass spectrometer 
(Thermo Fischer Scientific, Germany) coupled to an Eksigent nano LC system (Eksigent 
Technologies, USA). Peptide separation was made using self-packed (75 µm × 80 mm) reverse 
phase column packed with C18 material (AQ 3 m, 200A; Bischoff GmbH, Germany) as 
previously described in Mayank et al. (16).  
Data Refinement: After data collection peak lists were generated using Mascot Distiller 2.3 
(Matrix Science Inc., UK) and searched against a human database from SwissProt (release 
December 2012) concatenated with its decoyed version and an in-house build contaminant 
database using the Mascot search algorithm (Mascot 2.3; Matrix Science Inc., UK). The 
following search parameters were used: precursor ion mass tolerance 10 ppm; fragment ion mass 
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tolerance 0.8 Da; trypsin digestion (one missed cleavage allowed); fixed modifications of 
carbamidomethyl of cysteine; variable modification oxidation of methionine as well as pyro-Glu 
formation of peptide N-term glutamine. After the Mascot search data were further evaluated 
using Scaffold 4.3 (Proteome Software Inc., OR, USA). Thresholds for protein identification 
were set to 95% protein probability; 99% peptide probability and 2 peptides per protein. Final 
data processing was carried out using Microsoft Excel 2010 (Microsoft Corp) and presented in 
the Figure 1 and Supplemental Table S1. 
Database development and analysis 
Semi-automatic data mining: To identify a protein from different data sources, gene names 
and identifiers (e.g. IPI, UniProtKB, etc.) were queried in different ways. In the case of 
publications, the pdf file of the supplementary tables was converted to html format, while in the 
case of a web resource (e.g. hRBCD, BGMUT) contents were downloaded in html or text 
format. Python scripts were written and used to map gene names and identifiers to unique, when 
possible reviewed, UniProtKB entries. When this process failed, we tried to assign gene names 
or database identifiers manually to UniProtKB records. For example, in the case of unmatched 
IPI (International Protein Index) identifiers, different versions of the retired IPI database were 
downloaded (http://www.ebi.ac.uk/IPI) and searched. To convert GI numbers to UniProt 
accessions, the mapping API of UniProtKB was employed. In certain, relatively low number of 
cases our efforts to identify the target protein unambiguously failed because of obsolete entries 
and retired databases that are not existing or maintained any more. 
Software and tools: Membrane and membrane associated proteins were visualized  using 
various online resources: TMHMM2.0 (1), Protter (17) (http://wlab.ethz.ch/protter/start/), data 
from The Human Transmembrane Proteome Database (http://htp.enzim.hu), and different 
sections of UniProtKB including “Subcellular location” and “Features” were considered. The 
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database uses the MySQL relational database back-end (http://www.mysql.com) for data storage. 
For data access, the SQLAlchemy (http://www.sqlalchemy.org) object-relational mapper libraries 
were used. The web interface was created based on the TurboGears web framework 
(http://turbogears.org) and the Genshi templating library (http://genshi.edgewall.org). Selected 
data fields of UniProtKB (18) presented in the entry page of a protein are stored in a highly 
organized relational way, while the whole UniProtKB records are stored in a separate table, used 
exclusively for full text searches. Full text data from the sources were also inserted for certain 
proteins when it was possible (e.g. in the case of BGMUT(19)). To aid searches for proteins 
connected to diseases, we included OMIM (Online Mendelian Inheritance in Man, OMIM
®
. 
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, 
http://omim.org) data, mapped to protein entries for full text query possibility. Information about 
isoforms identified in our MS experiments is also inserted and made searchable. Data analysis 
was performed using python scripts and the R statistical package. 
 
Results and Discussion 
Mass spectrometry analysis of human RBC membranes and database comparisons  
When searching for the presence of red cell membrane proteins in mass spectrometry (MS) 
datasets on RBC, significant differences in the identified proteins between various MS studies 
were observed (see below). In order to test for the presence of membrane proteins and to 
understand the possible sources of differences, a mass spectrometry (MS) based proteomics study 
on isolated membranes (ghosts) of human red blood cells was performed in house. The 
preparation method (see Methods) was selected based on previous experience that this approach 
removes contaminating cell types and loosely membrane-bound cytoplasmic or plasma proteins 
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most efficiently. In order to assess the quality of our MS data, a comparative analysis with 
published human peripheral blood constituents proteome (20)
 
with a particular emphasis on 
proteins known to be expressed in potentially contaminating membranes. This analysis revealed 
that most of the identified proteins in our study are not present in blood constituents other than 
erythrocytes (Supplemental Figure 1, and Table 2) and that the level of contamination with non-
RBC markers was minimal (see (21)). As an important technical point, in order to try to enhance 
the efficacy of proteolysis in our MS studies, we included extensive deglycosylation of the 
proteins and screened for the most optimal proteolysis conditions (22). 
Three independent experiments were performed to detect membrane proteins, and the data 
are presented in Figure 1. We have identified altogether 419 proteins, 264 of them had predicted 
transmembrane domains or were labeled as membrane associated proteins in SwissProt (Figure 
1A, B). These 264 “membrane” proteins found in our MS study could be classified as integral, 
transmembrane (TM) proteins (167), and membrane associated (97) proteins. The other 
identified proteins in our RBC membrane preparations are probably soluble proteins, variably 
attaching to the membrane (155). Regarding the transmembrane proteins, in the three 
preparations we found 143-144-132 TM proteins, from which 115 were found in all three 
membrane preparations (Figure 1C). The small differences of the samples may result from both 
technical reasons and differences in protein expression of individual blood donors.  
In the following we have made a detailed comparison of our MS study results with various 
available data sources. The largest and most complete datasets of the erythrocyte membrane 
proteins can be found in MS-based studies. However, when we analyzed several of the most 
comprehensive MS-based datasets (6,7,10), we found only scattered overlaps (Figure 2). 
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Interestingly, out of the 264 membrane proteins identified in our current MS experiments, a 
relatively high number of proteins (141) were not listed in hRBCD, and 131 were not found in 
the dataset of Pesciotta et al. (11) In contrast, our study could not detect 86 proteins out of the 
209 membrane proteins listed in hRBCD and 171 out of the 304 proteins listed by Pesciotta et al 
(Figure 2A) (11). 
Our analysis of these and other MS-based data from publications (e.g. (21), (23)) was 
rendered to be more difficult or impossible in certain cases. An incomplete list of challenges 
includes identifiers pointing to non-human (e.g. rabbit, dog, mouse) protein entries, different GI 
numbers listed but pointing to the same gene, some of the GI numbers listed which do not match 
the corresponding UniProtKB accession listed in the same supplementary table, etc. Therefore 
we turned to reviews that already processed various MS-based studies. A major MS-based list of 
red cell membrane proteins has been compiled by D'Alessandro et al. (6) Although this list 
contains 512 membrane proteins, 125 proteins found in our study are not present in this dataset 
(Figure 2B). The recent RBC protein collection by Goodman et al. (10) lists 687 potential 
membrane proteins, with 85 unique entries, still leaving out a high number of RBC membrane 
proteins found in other sources we investigated  (Figure 2B).  
The red blood cell membrane proteins included in the CD system for erythrocyte antigens 
(http://www.hcdm.org), and proteins providing the molecular basis of blood group antigens, 
compiled in the human blood group database (BGMUT) at the NCBI web site (19) 
(http://www.ncbi.nlm.nih.gov/projects/gv/rbc/xslcgi.fcgi?cmd=bgmut/home) provide additional 
data sources in this regard. In both cases cell surface expressed proteins are validated by 
antibodies, and in many cases the related genetic background, modification patterns, etc. are also 
provided. Again, in a comparative analysis, we found that the CD list (containing 30 RBC 
membrane proteins) has 25 unique entries relative to all other databases, and the BGMUT 
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(containing 30 red cell membrane proteins) has 3 unique entries. Our MS-based dataset does not 
contain 27 members from the CD list and 6 proteins from BGMUT (Figure 2C and 
Supplemental Tables 3 and 4). Only further detailed experiments by applying various 
methodologies may help to resolve these inconsistencies. However, a properly constructed 
database may significantly help to explore these questions and promote further research in this 
regard. 
 
Generation of RBCC, an interactive database for red cell membrane proteins 
The use of the currently available resources is cumbersome or not sufficient to identify a 
membrane protein in RBC as a potential biomarker. Bioinformatics studies suffer  from 
identifying all RBC proteins from MS data sources (24). To overcome these difficulties we have 
generated the RBCC (Red Blood Cell Collection), a database and a web application allowing the 
storing and accessing of all experimentally identified RBCs proteins focusing the RBC 
membrane proteins (http://rbcc.hegelab.org).  
In this database we have integrated knowledge from various resources, including the hRBCD 
(7), reviews (6,10), the BGMUT database of blood group system (19), and the CD marker table 
provided by BD. Gene names and preferentially UniProtKB IDs were identified either 
automatically or manually. UniProtKB IDs are used in our database to uniquely identify 
proteins, since UniProtKB is currently one of the most stable and reliable protein identification 
systems (18). Moreover, our data are UniProtKB centered in a way that the basic properties of 
proteins (e.g. name, function, genetic variants, cross-references, etc.) are taken from this 
database, since it is a manually curated with high reliability. 
The resulting RBCC database now contains 2,638 unique protein entries, from which 846 are 
presumed “membrane” proteins (either labeled as transmembrane or membrane-associated 
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proteins), and out of these 376 are labeled as TM proteins, that contain predicted transmembrane 
regions. By default, the search function is currently constrained to the “membrane” proteins in 
the database.    
One of the main purposes of a database design is to help users with the ease of data 
accessibility. While it is usually legitimate and necessary to create the data storage in a relational 
database management system (RDBMS), this implementation does not allow an easy, google-
like search option – a problem faced on most of the biological databases available on the 
Internet. To have an improved and user-friendly search option (Supplemental Figure 2), we have 
employed the full text search possibilities of the RBDMS. In the result set and in the entry page 
of a protein (Supplemental Figure 3) selected data fields of UniProtKB are presented.  
Since in many cases the data sought by the users may not be present in UniProtKB, records 
from other databases are also inserted into the RBCC database. As an example, in order to help 
to find RBC membrane protein biomarkers related to diseases, the OMIM (Online Mendelian 
Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins 
University, Baltimore, MD, http://omim.org) records for the identified RBC membrane proteins 
are also presented. In addition, in our database registered users can make important comments 
(e.g. on quality of antibodies; verification of the presence of a protein in RBC by biochemical 
studies) which are also visible for following users. 
In order to assess the genetic background of a selected RBC membrane protein as a potential 
biomarker, our web application lists the available genetic variants and also hyperlinks to cross-
references selected from UniProtKB. In addition, we provide a link to Antibodypedia (25), 
containing validated antibodies against proteins, that readily aid the selection of an antibody to 
be tested in immunoedetection e.g. by flow cytometry. Antibodypedia is an alternative of the CD 
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antibody panels, containing also validated antibodies for the human proteome, not exclusively 
for the few hundred proteins in the CD system. 
 
Comparative analysis of data for membrane proteins in RBCs 
Recent databases provided a surprisingly large number of previously unexplored membrane 
proteins in the single plasma membrane compartment of the human erythrocytes. Moreover, it 
has been suggested that the quantitative expression levels of certain membrane proteins in the 
easily accessible RBC are closely related to different disease conditions (9,26). However, when 
trying to analyze and compare the available databases, we found an unexpected confusion and 
lack of confidence for RBC membrane proteins searches. 
Therefore, we have performed an own MS study on the isolated human RBC, and compared 
it with different available resources before assembling into a database for RBC membrane 
proteins (http://rbcc.hegelab.org). As detailed above, the current database containing 846 
“membrane protein” entries, based on many of the above mentioned datasets, most probably 
represents an overestimation of the potential RBC membrane protein constituent. Therefore we 
have also introduced “confidence” levels to evaluate the potential validity of the listed proteins. 
A low level was set, if the protein was identified only semi-automatically from reviews, in which 
case we are not able to assess the quality of the large number of sources in these review papers. 
A medium level was specified when the protein is present in either hRBCD (7), in the study of 
Pesciotta et al. (11), or in our MS samples. We compared the methodologies and the results of 
these MS studies and drew the conclusion that the differences may arise from problems of 
membrane protein MS (e.g. variability in protease accessibility or sample components caused by 
hydrophobic properties resulting in aggregation and/or adhesion to tube walls). We defined a 
high confidence level, when the protein was present in at least two MS studies (hRBCD (7), 
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PM22954596/Pesciotta et al. (11), and our work) or is an established blood group or CD marker. 
Although this is only a temporary, coarse grained setting of confidence levels in the database, 
this approach and further related studies may significantly help the decisions for selecting RBC 
membrane proteins as possible targets for research or diagnostic markers. 
In order to allow assessing whether or not a protein is a candidate diagnostic biomarker, we 
have extended the RBCC database to cover the available data for membrane protein function, the 
variability of the genetic background as well as the relationship with genetically determined 
human diseases. Thus the RBCC protein database and its search and command options presented 
here may significantly help the current, accelerated development of new biomarkers helping 
both stratified/personalized diagnostics and therapy. 
This database now contains an unexpected large number of validated membrane proteins 
previously thought to be specific for selected tissues and calls attention to RBC proteins related 
to major human diseases. As examples, among the RBC membrane proteins we find key ABC 
transporters (e.g. ABCC1-MRP1, ABCC4-MRP4, ABCG2–BCRP), more than 20 different 
solute carrier (SLC) type transporters, and an important copper-transporting ATPase. Virus and 
other infectious agent receptors, proteins involved in membrane lipid organization and 
modulation (e.g. phospholipid transporters and scramblases), signal transduction related proteins 
(e.g. interleukin receptors, RAS proteins, LIF receptor, G-protein regulated protein kinases, PI 
and PIP kinases, RAB, RAC, RAP, and RAS proteins), membrane scaffolding, trafficking and 
cell adhesion proteins (e.g. flotillin 1 and 2,  syntaxins, basigin, VCAM, ICAM) are also present 
with „high confidence”.  
Many of the proteins identified in red cell membrane are involved in the development of 
either monogenic or polygenic  diseases, e.g. proteins related to Alzheimer disease (e.g. the 
amyloid beta protein, alpha-synuclein, amyloid beta precursor protein-binding protein 1, 
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clusterin, presenilin-1; nicastrin, acetylcholinesterase, basigin, protein disulfide-isomerase), to 
metabolic syndromes (e.g. GLUT1, GLUT3, GLUT4, urea transporters, ferroportin, ABCG2, 
monocarboxylate transporter, aquaporins, cAMP-dependent protein kinase, G-protein subunits, 
diacylglycerol kinase, RHO kinases, nicastrin), or to hypertension (e.g. glucose transporters, the 
Band3 anion transporter, the K-Cl co-transporter 3, the KCNN4-Gardos channel, aquaporin1, 
plasma membrane ATPases, adducins, ankyrin, Hras, Kras and Nras, G alpha protein, IL 
receptors, dynamin, interferon and TNF receptors). A follow up study exploring the quantitative 
expression of the RBC membrane proteins, as already performed for ABCG2 (26), may provide 
key information regarding some of the above listed candidates. 
A reference RBC proteome and known caveats in determining the RBC proteome would be 
important also for therapeutic developments, involving erythrocytes generated from induced 
pluripotent stem cells (iPSC) (27). Although comparison of iPSC-derived erythroid cells to 
erythrocytes indicated highly overlapping proteomes, a significant number of both soluble and 
membrane proteins (e.g. CD44 responsible for the Indian blood group system, PMCA4, 
ABCG2) were not identified in cell lines in this MS-based study. These difficulties could lead to 
misinterpretation of the similarity levels (proteins present in the reference cell line but not 
detected and absent in the iPSC-derived erythroid cells), thus may result in false directions in 
therapeutic developments. 
It is interesting to note that when performing the analysis of our extended database, we did 
not find several clinically important membrane proteins, indicated by numerous earlier studies to 
be present in the erythrocyte membrane. There are several examples of such “outliers”, including 
the insulin receptor, the beta adrenergic receptor, and several ABC and SLC transporters. This 
may be a hint that even large scale proteomic studies may miss important information and 
further results of biochemical, genetic and immunlogical studies should be combined to have a 
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complete knowledge in this regard. In order to compensate for this clearly incomplete feature of 
the current RBC databases, we provided an “open correctibility” function in this database, so 
that the content of the database can be updated based on comments from registered users. 
 
Conclusions 
Numerous human membrane proteins became accepted clinical biomarkers and the 
determination of the easily accessible red blood cell (RBC) membrane proteins may provide new 
diagnostic possibilities in this regard. Since the current databases including our membrane 
specific proteomics presented in this work show large variations, we generated a comprehensive 
and expandable database for the RBC membrane proteins. The integrated web database now 
refers to proteomic, genetic and medical databases as well, and contains an unexpected large 
number of validated RBC membrane proteins previously thought to be specific for other tissues 
and/or related to major human diseases. This work should facilitate the development of RBC 
membrane biomarker platforms and provide a unique resource to aid further research and 
diagnostics. 
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Figure Legends 
 
Figure 1. Mass spectrometry results of 3 independent red cell membrane samples. (A) 
These MS experiments were reproducible, as indicated by the high number (304) of proteins 
identified in 3 individual experiments. (B, C) Detection of the RBC transmembrane and 
membrane associated proteins was also efficient. For methodological details see the Methods 
section. 
 
Figure 2. Comparison of the coverage of RBC transmembrane and membrane associated 
proteins in different datasets. (A) The presence of membrane proteins in mass spectrometry 
data sets, (B) in comprehensive reviews, and (C) in highly validated data sources are compered 
to membrane proteins identified in our mass spectrometry study. hRBCD: human RBC 
Database; Pesciotta et al., D’Alessandro et al., and Goodman et al. are references to (6,10,11); 
BGMUT and BD_CD mark the human blood group database and the CD marker table provided 
by BD, respectively. 
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Supporting Information Captions 
 
Figure S1. Comparison between the “exclusive human blood peripheral proteome” 
(Haudek et al., 2009) and the erythrocyte membrane proteome as determined in the present 
study. Additionally, 77 proteins are shared between more than one blood constituents proteome.  
 
Figure S2. RBCC (Red Blood Cell Collection) search options. Complex full text queries with 
examples and syntax at the bottom of the page can be entered. By default the search is 
constrained to membrane proteins. Depending on the objective of the query, the confidence of the 
presence of the matches can be set to low (only semi-automatic identification from reviews), 
medium (present in either hRBCD or BSc_CH), and high (present in both hRBCD and BSc_CH; 
a blood group or CD marker; experimentally tested in the Sarkadi-lab). The sources to use in the 
query can be also selected. 
 
Figure S3. The protein entry page in RBCC. List of sources, which have identified the 
presence of the protein in RBC, alternative names, genetic variants and links to other databases 
are shown in this page. A link to Antibodypedia aids to find an antibody for diagnostics 
development. Importantly, a pre-built PubMed query is also available to search for papers with 
all the alternative gene and protein names limiting the search containing alternatives of RBC (e.g. 
erythrocyte). If the user is logged in, he or she can leave comments for the entry in a box at the 
bottom of the page. 
 
Table S1. Proteins and peptide fragments identified in RBC ghosts by MS. 
 
Table S2. Hallmark proteins of different blood cell types present in our samples. 
 
Table S3. Erythrocyte membrane antigens listed in the CD system (http://www.hcdm.org). 
 
Table S4. Erythrocyte membrane proteins listed in the human blood group database 
(BGMUT) at the NCBI web site (http://www.ncbi.nlm.nih.gov/ 
projects/gv/rbc/xslcgi.fcgi?cmd=bgmut/home). 
